The global liquid biopsy market was valued at USD 9.63 billion in 2024 and is expected to grow from USD 11.66 billion in 2025 to USD 58.64 billion by 2032, registering a CAGR of 25.9% during the forecast period. In 2024, North America led the global liquid biopsy market, accounting for a 54.43% share.

The liquid biopsy market represents a transformative shift in the field of diagnostics, offering a non-invasive method for detecting and monitoring various types of cancer through the analysis of biomarkers in bodily fluids such as blood. This technique enables early detection, real-time monitoring of treatment effectiveness, and identification of genetic mutations without the need for traditional tissue biopsies. The growing demand for personalized medicine, coupled with advancements in genomic technologies and next-generation sequencing, has positioned the liquid biopsy market as a critical component of modern oncology care. As healthcare systems continue to prioritize early and accurate diagnosis, liquid biopsy is emerging as a valuable tool for improving patient outcomes and reducing the burden of invasive procedures. With its potential to enhance precision medicine, the liquid biopsy market is expected to play a vital role in the future of cancer diagnostics and therapeutic decision-making.

Tariff Impact Analysis for Liquid Biopsy Market:

**https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506**

Liquid Biopsy Market Overview:

The liquid biopsy market is gaining momentum as a revolutionary approach in cancer diagnostics and monitoring. Unlike traditional tissue biopsies, liquid biopsy is a minimally invasive technique that analyzes circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs) from bodily fluids, primarily blood. The increasing prevalence of cancer, the growing demand for early detection methods, and the rise of personalized medicine are significant factors driving the growth of the liquid biopsy market.

Market Segmentation:

• The liquid biopsy market can be segmented based on biomarker type, application, cancer type, and end-user:
• By Biomarker Type: The market includes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), RNA, and exosomes.
• By Application: Key applications include early cancer detection, treatment monitoring, recurrence detection, and companion diagnostics.
• By Cancer Type: The market addresses various cancers such as breast cancer, lung cancer, colorectal cancer, prostate cancer, and others.
• By End-User: Major end-users include hospitals, diagnostic laboratories, academic research centers, and biotechnology companies.

Key Companies Featured in the Liquid Biopsy Market Report:

• Guardant Health (U.S.)
• PERSONALIS, INC. (U.S.)
• FOUNDATION MEDICINE, INC. (U.S.)
• Natera, Inc. (U.S.)
• Illumina, Inc. (U.S.)